JFIFPhotoshop 3.08BIM@New Post-Hoc Analysis Explores Daily Oral Orforglipron Use in Ad720260510PSCIENMAGUAuthorxNew Post-Hoc Analysis Explores Daily Oral Orforglipron Use in Adults Over 65 with Obesity, Regardless of Diabetes Status Science@https://scienmag.com/new-post-hoc-analysis-explores-daily-oral-o© 2026 Sciencehttps://scienmag.com/hA groundbreaking new analysis set to be unveiled at the European Congress on Obesity (ECO 2026) in Istanbul delves into the efficacy and safety of orforglipron, an innovative oral glucagon-like peptide-1 receptor agonist (GLP-1 RA), in treating obesity among older adults aged 65 and above, both with and without type 2 diabetes mellitus (T2D). This […]ScienceMedMedicineMedicineATTAIN-1 and ATTAIN-2 studies(FDA approval for weight management drugs!geriatric obesity pharmacotherapy&GLP-1 receptor agonist in older adults$incretin-based therapies for elderlynon-peptide GLP-1 RA therapy$obesity management in adults over 65obesity treatment oral orforglipron use in elderly#orforglipron clinical trial results"orforglipron for obesity treatment orforglipron safety and efficacyC    !'"#%%%),($+!$%$C   $$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$"=!1AQa"2qB#3RSr4b$C%D)!1AQ"2R#B ? Vw."8+@,@ZRLeN8|W.-65yd,k۸%U"󴱭G!Z|ɮl]_TAkZi<:('8=^[XfS%.hFsBL 8^v-y4[(NA>nPXΊ@!1냌 [`PD?*&r0`9n=-pH_JYaIiʎ|GGd (=Yխ1 +"489)wF-0c]]J#3L&!sSmUQE`}$[{Ei[ }@ # IhowpB ׵-m&aeNkm2[H|%r({\sqz$Ff&VX9oYnZ@s_A_[ʚ=Ұ,Ŧpxl3GZ<7(bw\X'?J<#?'*oPm]4Oj jguT^bOigߚgzyxy=Hn%#%(_Omi[GOzUEAtkO&_6/<hJHr:W3)=BВ p*w~mY){'c21S(nwB-k>|6r~tC#|7V$(:XGwgZJ% -$9>+'`($>tc<ʹ19,U怑VY "U0x]P#j-#]97qĩa^.(Q?g8$硧nhY9P.ֽcuHeeII$fkShE<#*~G{-O,]?v98ܲG1 UdMSz }mʼhiv FsπP빷ˆ&z׏ -;y)*Tw䝦J-P78jT3y-cީn^ͻŷn cmǥY{) v[Fb=q Ue??{@Ҡ6z:FNxTfkOw/w5V#E95@}(rsj~0PǣߚG﫠#ntO Vo. NWnXNM*OcC}1.v{CZX߮+6}#M}\OTy&=;IfeX5 ݛq}+.E[HYP%so;rI ir!TJUCK68M^-QZ:C[׏<<^iE"cԍ7p;;G 7d8b6sthF{VӴ8kizGɒ{(n؏1TVi%2ώd{NJy Z"'0X 8ۢ9k}8 80s r&>BV+u "hb9UxsRP}V+_UX.q̚l$H$2j8@&IAl܁jݟֹ֠3mңv~=Տ+)wCZǽhʹ DVvʭIJ0?:.zZ `0XSI 1ۈd~Ш]$'jj6x{ Եy&2\LF8r@鯮eBO#) h U|a9_=~JןP4 LĻUuTM#MdzhC܎u! pq҅an 7GS?]R6I\ͯ-kQÅ*TѭD.}b׭h;t,t3*lΨsal6ZެS,qG|?J/7ΝhVEa`ig{szu:5e,O:ϳIɫN8 pGtz>w(DS/!C10BƤNW:T ŠZ5[{[F᭠%ȑ֕#&E=滺֥W&QԎ{ Sta۸Y6~Koɡ_[(̌x~-Mlo:볱VmwBbU UdZ7ES˹@TsYӯ_[ f܁GyPP{?Iw" ?]Wa:SB~#Chl',F)/yjFIk JT1J?e~VLS+\! %̌sʍs* z6J!sy ¦L$Am0č6s"Iot @?)#5E= @|&>튠sS N$+AZj/8n4Kn#AJdJ7QQ^KjB'Lش2iD(j46=荛TZy}d?N2K=o e [~rG3Z&m,1.|TƕٺjNʇFv0葄_rǹ7ӀҢ|Sq ̦r췓j(D|/Ҳ_1·Z75ݳӼrEi>.#h'sA6;]tXIYcc6nTy< +ÓCRJU_؟S߫_DfҴmbq N?A@Wۊuhf~d`jۗS39FFB:ʓQ.M46I SK@#?i3 㙏-ud["'c@lm=P ||74ޠgiQ1ƫ߹Y7lwQ#EUϯ?֢ rd mn7L0[/ ]2O{nm#3Mtp1NycjZ?4<>VoVSi{Fm.D.| %,nkvV:tc!Xk.=2=Zm cZSFD\PbZ]Iq"V0ܞYABȌf@ܛBq=^3*KH{n%?rqJ?ڭu?,)0tp'`$>?|nglM0qP~f]ըn 9N_bH@jׯG=+C$^<.9]JϏRuMRIT <5C.5>VO-xi_TωJ~O-*HS;2I]dymŝacrںϨ BHXj[=7PH8Q1;?/3C߶%HYiNWfN&9k"6ZI Κ۶껎زN{bT=7kaI/WaA3 KZwS!<^t)=xc3=g֕GޢN$ R1,e Оj[~'Ԓ U%dyijcu g~"u!.•Ct5_mvG"`X+X|Td$nmfqG0'jݦSVa]">ՊZX[Q<^@+{sRjM%ˆ'Үn${Ɵ괺|MHnwJD$S-,xR\¦"ac`R:;`˹ -Px8$҃rq9r 3QW <V85M vPJK' ^VcpB]݌*HX;59.!8WPYp:v'`! ^&yWƽc!RcLX&w*P{IuE3$D:m $Ҩk?*S'¿?U>W^{N) Ҏ>\R